Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748303 | 0.90 | POLB (0.47) | POLBNPC1LMNATSHRL3MBTL1 | |
| SCHEMBL4138303 | 0.86 | ALPL (0.49) | POLBTSHRL3MBTL1TDP1MAPT | |
| SCHEMBL3711859 | 0.83 | TDP1 (0.41) | POLBL3MBTL1TDP1MAPTKDM4E | |
| SCHEMBL12712571 | 0.81 | PTAFR (0.43) | POLBLMNATDP1MAPTKDM4E | |
| SCHEMBL10026437 | 0.81 | TSHR (0.51) | POLBNPC1TSHRL3MBTL1TDP1 | |
| SCHEMBL2346128 | 0.80 | KDM4E (0.59) | LMNATSHRL3MBTL1TDP1MAPT | |
| SCHEMBL19894133 | 0.79 | TSHR (0.51) | POLBNPC1LMNATSHRL3MBTL1 | |
| SCHEMBL1608842 | 0.79 | TSHR (0.49) | POLBNPC1TSHRL3MBTL1TDP1 | |
| SCHEMBL15324278 | 0.79 | MAPK11 (0.53) | LMNATDP1MAPTHTTJAK2 | |
| SCHEMBL30658173 | 0.79 | MAPK11 (0.53) | LMNATDP1MAPTHTTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461345-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461345-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2562158-A1 | Processes for the preparation of n-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes | Vertex Pharmaceuticals Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1603878-B1 | PROCESSES FOR THE PREPARATION OF N-HETEROARYL-N-ARYL-AMINES BY REACTING AN N-ARYL CARBAMIC ACID ESTER WITH A HALO-HETEROARYL AND ANALOGOUS PROCESSES | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316345-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316345-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-13 | — | — | US | disclosed |
| US-8273896-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273896-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273896-B2 | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120157684-A1 | PROCESSES FOR THE FACILE SYNTHESIS OF DIARYL AMINES AND ANALOGUES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100234606-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234606-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234606-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010093889-A2 | SOLID FORMS OF 2-(2, 4-DIFLUOROPHENYL)-6-(1-(2,6-DIFLUOROPHENYL)UREIDO)NICOTINAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093889-A2 | SOLID FORMS OF 2-(2, 4-DIFLUOROPHENYL)-6-(1-(2,6-DIFLUOROPHENYL)UREIDO)NICOTINAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093890-A2 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093890-A2 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010038428-A1 | ALTERNATIVE AGENT TO TAXANE ANTI-CANCER AGENT | 武田薬品工業株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157684-A1 | PROCESSES FOR THE FACILE SYNTHESIS OF DIARYL AMINES AND ANALOGUES THEREOF | ABL1, PNMT, MAOA | POLB 1356/4885NPC1 2399/4885LMNA 2302/4885 |
| US-20100234606-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | MAPK1, NADK, NAMPT | POLB 2097/4885NPC1 1612/4885LMNA 1944/4885 |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | ABL1, PNMT, MAOA | POLB 1356/4885NPC1 2399/4885LMNA 2302/4885 |
| US-20120316345-A1 | PROCESSES FOR PRODUCING PHENYL-6-(1-(PHENYL)UREIDO)NICOTINAMIDES) | MAPK1, NADK, NAMPT | POLB 2097/4885NPC1 1612/4885LMNA 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.